dc.contributor.author | Gennatas, S | |
dc.contributor.author | Chamberlain, F | |
dc.contributor.author | Smrke, A | |
dc.contributor.author | Stewart, J | |
dc.contributor.author | Hayes, A | |
dc.contributor.author | Roden, L | |
dc.contributor.author | Messiou, C | |
dc.contributor.author | Kowa, J-Y | |
dc.contributor.author | Estival, A | |
dc.contributor.author | Chauhan, D | |
dc.contributor.author | Thway, K | |
dc.contributor.author | Fisher, C | |
dc.contributor.author | van der Graaf, WTA | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Benson, C | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-09-01T09:26:34Z | |
dc.date.available | 2022-09-01T09:26:34Z | |
dc.date.issued | 2020-10-02 | |
dc.identifier.citation | The Oncologist, 2020, 25 (12), pp. e2013 - e2016 | en_US |
dc.identifier.issn | 1083-7159 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5363 | |
dc.identifier.eissn | 1549-490X | |
dc.identifier.eissn | 1549-490X | |
dc.identifier.doi | 10.1002/ONCO.13516 | |
dc.description.abstract | INTRODUCTION: Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent oral vinorelbine. MATERIALS AND METHODS: A retrospective review of patients treated with vinorelbine 90 mg orally on days 1, 8, and 15 of a 28-day cycle from January 2004 to July 2019 was performed. Response was assessed using RECIST version 1.1. Descriptive statistics were employed. RESULTS: A total of 29 patients were included. Response rate was 20.7% (6/29), and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%), and diarrhea (4/26, 13.8%). CONCLUSION: Single-agent oral vinorelbine is an effective, safe, and well-tolerated treatment for DT. It represents a new oral alternative for management of DT. | |
dc.format | Print-Electronic | |
dc.format.extent | e2013 - e2016 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | WILEY | en_US |
dc.relation.ispartof | The Oncologist | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Administration, Oral | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Fibromatosis, Aggressive | |
dc.subject | Humans | |
dc.subject | Retrospective Studies | |
dc.subject | Treatment Outcome | |
dc.subject | Vinblastine | |
dc.subject | Vinorelbine | |
dc.title | A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-08-24 | |
dc.date.updated | 2022-09-01T09:26:08Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1002/ONCO.13516 | en_US |
rioxxterms.licenseref.startdate | 2020-10-02 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32918789 | |
pubs.issue | 12 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery | |
pubs.publication-status | Published | |
pubs.volume | 25 | |
icr.researchteam | Sarcoma&Melanoma Surgery | en_US |
dc.contributor.icrauthor | Hayes, Andrew | |
dc.contributor.icrauthor | Messiou, Christina | |
dc.contributor.icrauthor | Jones, Robin | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-01. Deposit type is initial. No. of files: 1. Files: A Timely Oral Option Single-Agent Vinorelbine in Desmoid Tumors.pdf | |